Pharma & Biotech

Bayer's recently published annual report for 2025 delivers an unambiguous message: the legal risks associated with glyphosate continue to overshadow...

All eyes are on ImmunityBio today as the biotechnology firm prepares to release its full-year 2025 results. This follows the...

Biopharmaceutical firm Ocugen has achieved a significant clinical development goal just two days before its annual financial report. Company leadership...

NRx Pharmaceuticals is bolstering its executive team with a strategic hire aimed at accelerating the development of novel neuroplastic treatments....

Eterna Therapeutics has drawn significant market attention following a substantial insider purchase and the release of an updated corporate strategy....

The story of Danimer Scientific, once a celebrated pioneer in bioplastics, has reached its definitive conclusion on the public markets....

The biopharmaceutical firm Helix BioPharma is intensifying its development of highly targeted cancer treatments. Recent data presentations for its CEACAM6-targeting...

The clinical development pipeline at Avenue Therapeutics is progressing, with recent strategic moves placing several drug candidates in the spotlight....

The coming year represents a critical juncture for Viking Therapeutics, a biotechnology firm whose clinical pipeline is drawing significant investor...

The investment community is closely monitoring Outlook Therapeutics as it navigates a decisive period for its flagship ophthalmic drug. While...